ImmunoGen, Inc. Watch

from 10-Q 3 pages ​ ​ August 4, 2023 Lauren White 16 Laudholm Rd Newton, Ma 02458 ​ Dear Lauren: ​ I Am Delighted to Offer You the Full-Time Position of Senior Vice President, Chief Financial Officer at Immunogen, Inc. (“Immunogen or the “Company”). the Terms and Conditions of This Offer Are Set Out Below. We Look Forward to You Joining Immunogen. ​

from 10-Q 11 pages Change in Control Severance Agreement

from 10-Q 3 pages Immunogen, Inc. Compensation Policy for Non-Employee Directors

from 8-K 26 pages May 1, 2023 Immunogen, Inc. 830 Winter Street Waltham, Ma 02451 Attn: Mark J. Enyedy, Chief Executive Officer Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen

from 10-Q 78 pages License and Option Agreement

from 10-K 4 pages Immunogen, Inc. ​ ​ Restricted Stock Unit Terms and Conditions ​

from 10-K 22 pages Inducement Equity Incentive Plan, as Amended ​

from 10-K 5 pages ​ Immunogen, Inc. Compensation Policy for Non-Employee Directors

from 10-K 2 pages ​ ​ December 7, 2022 Michael J. Vasconcelles ​ Re: First Amendment to Offer Letter ​ Dear Mike: ​ Further to Our Conversation and in Reference to the Terms of Your Offer Letter Dated November 12, 2022 (The “Offer Letter”), This First Amendment to the Offer Letter (The “First Amendment”) Sets Out the Understanding Between US and Modifications to the Offer Letter as Follows: ​ 1. Unless Otherwise Specifically Set Forth Below, Any Capitalized Terms Used in This First Amendment Shall Have the Meanings Ascribed to Them in the Offer Letter. 2. Effective as of the Date of This First Amendment to the Offer Letter, Numbered Paragraph 8 of the Offer Letter Shall Be Amended as Follows

from 10-K 4 pages November 12, 2022 Michael J. Vasconcelles ​ Dear Mike: I Am Delighted to Offer You the Full-Time Position of Executive Vice President, Research, Development, and Medical Affairs at Immunogen, Inc. (“Immunogen” or the “Company”). This Offer Is Made Based on the Following Terms: 1. Reporting. Your Role as the Executive Vice President, Research, Development, and Medical Affairs. This Is a Corporate Officer Position and Is Considered an Executive Officer Position for Purposes of the Severance Pay Plan. in Your Role, You Will Report Directly to Me. 2. Start Date. Your Anticipated First Day of Employment Will Be No Later Than January 3, 2023 (The “Start Date”), Subject to Change by Mutual Agreement Between You and Immunogen

from 10-K 15 pages Addendum a to Michael J. Vasconcelles Offer Letter Change in Control Severance Agreement

from 10-K 15 pages Change in Control Severance Agreement

from 10-K 17 pages Immunogen, Inc. 2004 Non-Employee Director Compensation and Deferred Share Unit Plan

from 10-K 4 pages Restricted Stock Unit Agreement for Non-Employee Directors Under the Immunogen, Inc. Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan

from 10-K 6 pages ​ Immunogen, Inc. ​ Non-Qualified Stock Option Terms and Conditions

from 10-K 4 pages ​ Immunogen, Inc. Restricted Stock Unit Terms and Conditions ​

from 10-Q 21 pages Immunogen, Inc. ​ Inducement Equity Incentive Plan, as Amended ​ ​ ​ 1. Definitions. ​ Unless Otherwise Specified or Unless the Context Otherwise Requires, the Following Terms, as Used in This Immunogen, Inc. Inducement Equity Incentive Plan, Have the Following Meanings: ​ Administrator Means the Board of Directors, Unless It Has Delegated Power to Act on Its Behalf to the Committee, in Which Case the Administrator Means the Committee. ​ Affiliate Means a Corporation Which, for Purposes of Section 424 of the Code, Is a Parent or Subsidiary of the Company, Direct or Indirect. ​ Agreement Means an Agreement Between the Company and a Participant Delivered Pursuant to the Plan, in Such Form as the Administrator Shall Approve. ​ Board of Directors Means the Board of Directors of the Company. ​

from 8-K 23 pages Immunogen, Inc. Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan

from 10-Q 63 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Triple Asterisks Denote Omissions. License Agreement by and Between Immunogen, Inc. and Eli Lilly and Company

from 10-K 3 pages ​ Immunogen, Inc. Compensation Policy for Non-Employee Directors